WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012045569) FACTOR II AND FIBRINOGEN FOR TREATMENT OF HAEMOSTATIC DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/045569    International Application No.:    PCT/EP2011/066241
Publication Date: 12.04.2012 International Filing Date: 19.09.2011
IPC:
A61K 38/36 (2006.01), A61K 38/48 (2006.01), A61P 7/04 (2006.01)
Applicants: MEDIMMUNE LIMITED [GB/GB]; Milstein Building Granta Park Cambridge Cambridgeshire CB21 6GH (GB) (For All Designated States Except US).
LOVGREN, Ann [SE/SE]; (SE) (For US Only).
HANSSON, Kenny [SE/SE]; (SE) (For US Only)
Inventors: LOVGREN, Ann; (SE).
HANSSON, Kenny; (SE)
Agent: MYERS, Jonathan; MedImmune Limited Milstein Building Granta Park Cambridge Cambridgeshire CB21 6GH (GB)
Priority Data:
61/390,224 06.10.2010 US
Title (EN) FACTOR II AND FIBRINOGEN FOR TREATMENT OF HAEMOSTATIC DISORDERS
(FR) FACTEUR II ET FIBRINOGÈNE POUR LE TRAITEMENT DE TROUBLES HÉMOSTATIQUES
Abstract: front page image
(EN)The present invention relates to normalizing impaired haemostasis comprising administering a clotting factor treatment selected from the group consisting of (1) FII; (2) PCC; and (3) a three factor combination of FII, FX, and FVIIa. The clotting factor treatment can be administered in combination with fibrinogen. The clotting factor(s) can be recombinant human clotting factor(s).
(FR)La présente invention concerne la normalisation d'un dysfonctionnement hémostatique comprenant l'administration d'un traitement par un facteur de coagulation choisi dans le groupe constitué par (1) FII; (2) PCC; et (3) une combinaison de trois facteurs, FII, FX et FVIIa. Le traitement par facteur de coagulation peut être administré en association avec le fibrinogène. Le ou les facteurs de coagulation peuvent être des facteurs de coagulation humains recombinants.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)